Stem cell composition
US-10400218-B2 · Sep 3, 2019 · US
Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer
US12473547B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12473547-B2 |
| Application number | US-201816766206-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2018 |
| Priority date | Nov 22, 2017 |
| Publication date | Nov 18, 2025 |
| Grant date | Nov 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of treating a cancer in a subject, the method comprising administering to the subject a composition comprising mesenchymal precursor cells (MPCs) or mesenchymal stem cells (MSCs), wherein said MPCs or MSCs comprise an siRNA to KRAS G12D and contact target cancer cells in the subject, whereby the MPCs or MSCs form gap junctions with the contacted target cancer cells, and wherein said cancer comprises an oncogenic G12D mutation in KRAS. 2 . The method of claim 1 , wherein the composition comprises MPCs. 3 . The method of claim 2 , wherein the MPCs express tissue non-specific alkaline phosphatase (TNAP). 4 . The method of claim 1 , wherein the cancer is prostate cancer. 5 . The method of claim 1 , wherein the cancer is a pancreatic cancer or a colorectal cancer. 6 . The method of claim 1 , wherein the MPCs or MSCs are culture- expanded. 7 . The method of claim 1 , wherein the MPCs or MSCs are derived from pluripotent cells. 8 . The method of claim 1 , wherein the target cancer cells are non- syncytial cancer cells. 9 . The method of claim 1 , wherein the target cancer cells are syncytial cells. 10 . The method of claim 1 , wherein the MPCs or MSCs express a viral vector.
Assignees
Inventors
Classifications
Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214) · CPC title
Special delivery means, e.g. tissue-specific · CPC title
MicroRNAs, miRNAs · CPC title
Antisense · CPC title
Transferases (2) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12473547B2 cover?
- The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.
- Who is the assignee on this patent?
- Mesoblast Int Sarl
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).